Santalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis

Press/Media: Press / Media

PeriodMay 9 2017

Media coverage

4

Media coverage

  • TitleSantalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis
    Media name/outletTMC Net
    CountryUnited States
    Date5/9/17
    PersonsJohn C Browning
  • TitleSantalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis
    Media name/outletNasdaq
    CountryUnited States
    Date5/9/17
    PersonsJohn C Browning
  • TitleSantalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis
    Media name/outletCustomer Zone 360.com
    CountryUnited States
    Date5/9/17
    PersonsJohn C Browning
  • TitleSantalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis
    Media name/outletPharmacy Choice
    CountryUnited States
    Date5/9/17
    PersonsJohn C Browning